《高盛認股證牛熊證》平安好醫生突破80元水平 留意貼價購21302、高槓桿購23647
平安好醫生(1833)
正股表現：平安好醫生升約7.2%。今早繼續上升，最高見81.8元，突破一個半月高位。現報80.9元，升約2.4%。平安好醫生本週三表示，旗下互聯網醫院已打通湖北省醫保在線支付，並成為全球首個打通醫保在線支付的互聯網醫療平台。
資金流向：觀察個股認股證資金流向，可見昨日資金轉向部署認購證，錄得約110萬元資金流入。
產品選擇：投資者如看好，可考慮以行使價80至95元作為篩選認購證的條件。並可留意當中槓桿最突出之一的平醫購21302。並可留意價外幅度約15%，年期約4個月的平醫購23647。
平醫購21302，行使價88.88元，2020年07月31日到期，實際槓桿4.1倍，行使價80至95元間產品中，槓桿最高之一
平醫購23647，行使價92.93元，2020年07月24日到期，實際槓桿4.2倍，高槓桿、低街貨
石藥(1093)
正股表現：石藥昨日反彈升約1.2%。今早繼續上升，現報15.34元，升約2.1%。有券商預期石藥今年維持收入增長在約20%，並給予「增持」評級，目標價21元。
資金流向：觀察個股認股證資金流向，可見近期資金傾向部署認購證，過去5個交易日共錄得約350萬元資金流入。
產品選擇：觀察市場上的認購證，可見撇除兩個月期以下的產品後，共有31隻產品供選擇。投資者如看好，可留意當中槓桿最突出之一的低面值石藥購21872。
石藥購21872，行使價20.3元，2020年06月22日到期，實際槓桿9.0倍，低面值、兩個月期以上產品中，槓桿最高之一
註: 以上數據資料來自高盛認股證牛熊證網站~
重要聲明:
以上資訊由第三方提供，AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告，不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料，本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
